mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2019-4-79-83mrj-962Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSВопросы безопасности и оптимального дозирования ингибитора интерлейкина 17А (секукинумаб) при лечении псориатического артрита у пациента с сопутствующим вирусным гепатитом СThe safety and optimal dosage of an interleukin-17A inhibitor (secukinumab) in the treatment of psoriatic arthritis in a patient with concomitant hepatitis C virus infectionГубарьЕ. Е.GubarE. E.

Елена Ефимовна Губарь

115522, Москва, Каширское шоссе, 34А

Elena Efimovna Gubar

34A, Kashirskoe Shosse, Moscow 115522

gubarelena@yandex.ruКоротаеваТ. В.KorotaevaT. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

СтарковаА. С.StarkovaA. S.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

УрумоваМ. М.UrumovaM. M.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation2019231020191347983Copyright © Губарь Е.Е., Коротаева Т.В., Старкова А.С., Урумова М.М., 20192019Губарь Е.Е., Коротаева Т.В., Старкова А.С., Урумова М.М.Gubar E.E., Korotaeva T.V., Starkova A.S., Urumova M.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/962

Псориатический артрит (ПсА) – хроническое воспалительное заболевание из группы спондилоартритов, ассоциированное с псориазом. Решающая роль в патогенезе ПсА отводится активации оси интерлейкин (ИЛ) 23/ИЛ17 [1]. Секукинумаб (СЕК) представляет собой полностью человеческие антитела, которые связываются с ИЛ17А человека и нейтрализуют активность этого цитокина. Наличие у пациента сопутствующих заболеваний, в частности хронического вирусного гепатита В и вирусного гепатита С (ВГС), ограничивает применение ингибиторов фактора некроза опухоли α в лечении ПсА [2, 3].

Приведено клиническое наблюдение, демонстрирующее успешное лечение СЕК у пациента с ПсА и сопутствующим ВГС. Помимо аспектов безопасности применения СЕК при хроническом ВГС, обсуждаются вопросы оптимального дозирования препарата.

Psoriatic arthritis (PsA) is a chronic inflammatory disease of the group of spondylitides, which is associated with psoriasis. The decisive role is played by the activation of the interleukin (IL)-23/IL-17 axis in the pathogenesis of PsA [1]. Secukinumab (SEC) is a fully human antibody that binds to human IL-17A and neutralizes the activity of this cytokine. That the patient has concomitant diseases, chronic hepatitis B virus infection and hepatitis C viral (HCV) infection in particular, limits the use of tumor necrosis factor- α inhibitors in the treatment of PsA [2, 3]. The paper describes a clinical case that demonstrates the successful treatment with SEC in a patient with PsA and concomitant HCV infection. In addition to the safety aspects of the use of SEC to treat chronic HCV infection, the issues on optimal dosing of the drug are discussed.

псориатический артритхронический вирусный гепатит Ссекукинумабpsoriatic arthritischronic hepatitis C virus infectionsecukinumabReferencesНасонов ЕЛ. Новые возможности фармакотерапии иммуновоспалительных ревматических заболеваний: фокус на ингибиторы интерлейкина 17. Научно-практическая ревматология. 2017;55(1):68–86. doi: 10.14412/1995-4484-2017-68-86Nasonov EL. New possibilities of pharmacotherapy for immunoinflammatory rheumatic diseases: a focus on inhibitors of interleukin-17. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2017;55(1):68–86. (In Russ.). doi: 10.14412/1995-4484-2017-68-86Furst DE, Keystone EC, Kirkham B, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii2-25. doi: 10.1136/ard.2008.100834.Furst DE, Keystone EC, Kirkham B, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii2-25. doi: 10.1136/ard.2008.100834.Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of antitumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford). 2011 Sep;50(9): 1700-11. doi: 10.1093/rheumatology/ker190. Epub 2011 Jun 20.Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of antitumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford). 2011 Sep;50(9): 1700-11. doi: 10.1093/rheumatology/ker190. Epub 2011 Jun 20.Коротаева ТВ. Перспективы применения ингибиторов интерлейкина 17 – нового класса препаратов для таргетной терапии псориатического артрита. Научно-практическая ревматология. 2016;54(3): 346-51.Korotaeva TV. Prospects for using interleukin-17 inhibitors, a new class of drugs for targeted therapy of psoriatic arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2016; 54(3):346-51. (In Russ.). doi: 10.14412/1995-4484-2016-346-351Mease PJ, McInnes IB, Kirkham B, et al. FUTURE 1 Study Group Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015 Oct;373(14):1329-39. doi: 10.1056/NEJMoa1412679.Mease PJ, McInnes IB, Kirkham B, et al. FUTURE 1 Study Group Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015 Oct;373(14):1329-39. doi: 10.1056/NEJMoa1412679.McInnes IB, Mease PJ, Ritchlin CT, et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology (Oxford). 2017 Nov 1;56(11): 1993-2003. doi: 10.1093/rheumatology/kex301.McInnes IB, Mease PJ, Ritchlin CT, et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology (Oxford). 2017 Nov 1;56(11): 1993-2003. doi: 10.1093/rheumatology/kex301.Губарь ЕЕ, Логинова ЕЮ, Коротаева ТВ. Успешное применение ингибитора интерлейкина 17 (секукинумаба) в лечении изолированного деструктивного энтезита при псориатическом артрите. Научно-практическая ревматология. 2018;56(5):667-70. doi: 10.144121/1995-4484-2018-667-670Gubar' EE, Loginova EYu, Korotaeva TV. Successful use of an interleukin 17 inhibitor (secukinumab) in the treatment of isolated destructive enthesitis in psoriatic arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2018;56(5):667-70. (In Russ.). doi: 10.144121/1995-4484-2018-667-670Chiu HY, Chen CH, Wu MS, et al. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol. 2013 Dec;169(6):1295-303. doi: 10.1111/bjd.12461.Chiu HY, Chen CH, Wu MS, et al. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol. 2013 Dec;169(6):1295-303. doi: 10.1111/bjd.12461.Mori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. World J Gastroenterol. 2015 Sep 28;21(36): 10274-89. doi: 10.3748/wjg.v21.i36.10274.Mori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. World J Gastroenterol. 2015 Sep 28;21(36): 10274-89. doi: 10.3748/wjg.v21.i36.10274.Coates LC, Kavanaugh A. Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016 May; 68(5):1060-71. doi: 10.1002/art.39573. Epub 2016 Mar 23.Coates LC, Kavanaugh A. Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016 May; 68(5):1060-71. doi: 10.1002/art.39573. Epub 2016 Mar 23.Chiu HY, Hui RC, Huang YH, et al. Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study. Acta Derm Venereol. 2018 Oct 10;98(9):829-834. doi: 10.2340/00015555-2989.Chiu HY, Hui RC, Huang YH, et al. Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study. Acta Derm Venereol. 2018 Oct 10;98(9):829-834. doi: 10.2340/00015555-2989.Huang Z, van Velkinburgh JC, Ni B, Wu Y. Pivotal roles of the interleukin-23/T helper 17 cell axis in hepatitis B. Liver Int. 2012 Jul;32(6):894-901. doi: 10.1111/j.1478-3231.2012.02764.x. Epub 2012 Feb 19.Huang Z, van Velkinburgh JC, Ni B, Wu Y. Pivotal roles of the interleukin-23/T helper 17 cell axis in hepatitis B. Liver Int. 2012 Jul;32(6):894-901. doi: 10.1111/j.1478-3231.2012.02764.x. Epub 2012 Feb 19.Papp K, Gottlieb AB, Naldi L, et al. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015 Jul;14(7):706-14.Papp K, Gottlieb AB, Naldi L, et al. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015 Jul;14(7):706-14.Van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016 Jul;75(1):83-98.e4. doi: 10.1016/j.jaad.2016.03.024. Epub 2016 May 12.Van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016 Jul;75(1):83-98.e4. doi: 10.1016/j.jaad.2016.03.024. Epub 2016 May 12.Lu C, Wallace B, Fu W, et al. Efficacy and Safety of Novel Targeted Synthetic DMARD and Biological DMARD in Active Psoriatic Arthritis: A Systematic Review, Meta-Analysis, and Network Meta-Analysis [abstract]. Arthritis Rheumatol. 2018; 70(suppl 10):696.Lu C, Wallace B, Fu W, et al. Efficacy and Safety of Novel Targeted Synthetic DMARD and Biological DMARD in Active Psoriatic Arthritis: A Systematic Review, Meta-Analysis, and Network Meta-Analysis [abstract]. Arthritis Rheumatol. 2018; 70(suppl 10):696.Вeodhar AA, Gladman DD, McInnes IB, et al. Post-Marketing Safety of Secukinumab in Adult Patients with Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Cumulative Analysis across >96,000 Patient-Treatment Years Exposure [abstract]. Arthritis Rheumatol. 2018;70(suppl 10):2582Вeodhar AA, Gladman DD, McInnes IB, et al. Post-Marketing Safety of Secukinumab in Adult Patients with Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Cumulative Analysis across >96,000 Patient-Treatment Years Exposure [abstract]. Arthritis Rheumatol. 2018;70(suppl 10):2582Edwards CJ, Fautrel B, Schulze-Koops H, et al. Dosing down with biologic therapies: a systematic review and clinicians’ perspective. Rheumatology (Oxford). 2017 Nov 1;56(11): 1847-1856. doi: 10.1093/rheumatology/kew464.Edwards CJ, Fautrel B, Schulze-Koops H, et al. Dosing down with biologic therapies: a systematic review and clinicians’ perspective. Rheumatology (Oxford). 2017 Nov 1;56(11): 1847-1856. doi: 10.1093/rheumatology/kew464.Moverley AR, Coates LC, Helliwell PS. Can biologic therapies be withdrawn or tapered in psoriatic arthritis? Clin Exp Rheumatol. 2013 Jul-Aug;31(4 Suppl 78): S51-3. Epub 2013 Oct 4.Moverley AR, Coates LC, Helliwell PS. Can biologic therapies be withdrawn or tapered in psoriatic arthritis? Clin Exp Rheumatol. 2013 Jul-Aug;31(4 Suppl 78): S51-3. Epub 2013 Oct 4.Brahe CH, Krabbe S, Ostergaard M, et al. Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care – 2-year outcomes and predictors. Rheumatology (Oxford). 2019 Jan 1; 58(1):110-119. doi: 10.1093/rheumatology/key244.Brahe CH, Krabbe S, Ostergaard M, et al. Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care – 2-year outcomes and predictors. Rheumatology (Oxford). 2019 Jan 1; 58(1):110-119. doi: 10.1093/rheumatology/key244.Huynh DH, Boyd TA, Etzel CJ, et al. Persistence of low disease activity after tumor necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis. RMD Open. 2017 Jan 16;3(1):e000395. doi: 10.1136/rmdopen-2016-000395. eCollection 2017.Huynh DH, Boyd TA, Etzel CJ, et al. Persistence of low disease activity after tumor necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis. RMD Open. 2017 Jan 16;3(1):e000395. doi: 10.1136/rmdopen-2016-000395. eCollection 2017.Ruta S, Marin J, Felquer ML, et al. Utility of Power Doppler Ultrasound–detected Synovitis for the Prediction of Short-term Flare in Psoriatic Patients with Arthritis in Clinical Remission. J Rheumatol. 2017 Jul; 44(7):1018-1023. doi: 10.3899/jrheum.161347. Epub 2017 May 1.Ruta S, Marin J, Felquer ML, et al. Utility of Power Doppler Ultrasound–detected Synovitis for the Prediction of Short-term Flare in Psoriatic Patients with Arthritis in Clinical Remission. J Rheumatol. 2017 Jul; 44(7):1018-1023. doi: 10.3899/jrheum.161347. Epub 2017 May 1.Husic R, Gretler J, Felber A, et al. Disparity between ultrasound and clinical findings in psoriatic arthritis. Ann Rheum Dis. 2014 Aug;73(8):1529-36. doi: 10.1136/annrheumdis-2012-203073. Epub 2013 Jun 5.Husic R, Gretler J, Felber A, et al. Disparity between ultrasound and clinical findings in psoriatic arthritis. Ann Rheum Dis. 2014 Aug;73(8):1529-36. doi: 10.1136/annrheumdis-2012-203073. Epub 2013 Jun 5.Alivernini S, Tolusso B, Petricca L, et al Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission? Ann Rheum Dis. 2017 Jul;76(7):1228-1236. doi: 10.1136/annrheumdis-2016-210424. Epub 2017 Jan 24.Alivernini S, Tolusso B, Petricca L, et al Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission? Ann Rheum Dis. 2017 Jul;76(7):1228-1236. doi: 10.1136/annrheumdis-2016-210424. Epub 2017 Jan 24.Canzoni M, Piga M, Zabotti A, et al. Clinical and ultrasonographic predictors for achieving minimal disease activity in patients with psoriatic arthritis: the UPSTREAM (Ultrasound in Psoriatic arthritis TREAtMent) prospective observational study protocol. BMJ Open. 2018 Jul 10;8(7):e021942. doi: 10.1136/bmjopen-2018-021942.Canzoni M, Piga M, Zabotti A, et al. Clinical and ultrasonographic predictors for achieving minimal disease activity in patients with psoriatic arthritis: the UPSTREAM (Ultrasound in Psoriatic arthritis TREAtMent) prospective observational study protocol. BMJ Open. 2018 Jul 10;8(7):e021942. doi: 10.1136/bmjopen-2018-021942.

The authors declare that there are no conflicts of interest present.